 |
 |
 |
| |
De: PR Newswire
Brasil
Para: THERESA CATHARINA DE GÓES CAMPOS
Assunto: New Data Shed Light on the Global
Incidence of Constipation
New Data Shed Light on the Global Incidence of
Constipation
BN003644 23 de maio de 2006 14:11 HORALOCAL
New Data Shed Light on the Global Incidence of
Constipation
Not For Distribution or Publication in The
United States
INGELHEIM, Germany, May 23 /PRNewswire/ -- New
omnibus data from the
largest global survey due to be published,
conducted on the
epidemiology of constipation, were presented
today at the Digestive
Disease Week congress in Los Angeles. The survey,
sponsored by
Boehringer Ingelheim, offers new insights into
the incidence of
constipation and shows that sufferers are not
using the most
effective treatments.
The epidemiology survey, which explored duration
and frequency of
constipation in 13,879 participants from four
continents, shows 12%
of people worldwide suffer from self-defined
constipation. This figure
varies among different regions; people in the
Americas and Asia
Pacific suffer twice as much as their European
counterparts, where
the incidence of constipation is lowest (Americas
and Asia Pacific
mean 17.3% -v- European mean 8.75%).(1)
The survey also highlights that a quarter of
people suffering from
constipation do nothing to alleviate their
symptoms; they would
rather wait in the hope that it may go away of
its own accord.
Professor Scarpignato, one of the lead authors
of the survey,
commented, "Unfounded concerns and misguided
beliefs often prevent
constipation sufferers from using the best
available treatments, such
as contact laxatives. If they did use a contact
laxative, like
Dulcolax(R), they would be selecting a safe and
effective treatment,
to relieve their condition."
Of those constipation sufferers who treat their
condition, less than
a third of them actually use laxatives, despite
the fact that a
recently published review showed that laxatives
are a safe and
effective treatment.(2) In Asia Pacific, which
has one of the highest
frequencies of constipation (17%), laxative use
is lowest, with less
than two in 10 sufferers treating symptoms
effectively with a
laxative. Even in the Americas, where laxative
treatment is highest,
still less than four in 10 sufferers use
laxative treatments to
alleviate their constipation.(1)
Professor Wald, the lead author of the survey,
stated, "Sufferers
continue to be highly influenced and misguided
by myths surrounding
constipation and it is critical to correct and
overcome these
mistaken beliefs. This survey reveals that on
average, 40% of
sufferers attempt to treat their constipation by
changing their
nutrition, despite extensive research showing
that in fact diet and
lifestyle are not necessarily to blame for the
occurrence of
constipation and increasing fluid and fibre
intake will not
definitely provide effective relief from the
condition."
Professor Wald continued, "The new evidence from
the survey has
revealed that there is still a considerable
unmet need in the
treatment of constipation. It is our
responsibility to make people
aware of, and to offer, the best solutions for
constipation, by
publicising the facts and correcting these
misunderstandings."
Dulcolax(R) (bisacodyl or sodium picosulphate),
offers one such
highly effective and safe solution. It is a
widely available contact
laxative licensed for the treatment of
constipation and is commonly
used by millions of people worldwide. The active
ingredients in
Dulcolax(R) (bisacodyl or sodium picosulphate)
act only where they
are needed, in the colon,(3-18) and stimulate
the natural movements of
the bowels to alleviate the symptoms of
constipation. Dulcolax(R) is
clinically proven to be a safe(16,17,19,20) and
effective treatment
for constipation(20-23) even over the long-term.(24)
The epidemiology survey has led to further
investigations,
specifically of frequent constipation sufferers
(those who have
suffered for at least two years and at least
once every two to three
months), which aims to provide a complete and
full picture of this
group. Results from this pioneering
investigation are expected to be
presented at the 14th United European
Gastroenterology Week in
Berlin, Germany from 21-25 October 2006.
Notes to Editors
Digestive Disease Week (DDW)
DDW is the largest international gathering of
physicians, researchers
and academics in the fields of gastroenterology,
hepatology,
endoscopy and gastrointestinal surgery. Jointly
sponsored by the
American Association for the Study of Liver
Diseases, the American
Gastroenterological Association, the American
Society for
Gastrointestinal Endoscopy and the Society for
Surgery of the
Alimentary Tract, DDW takes place May 20-25,
2006, at the Los Angeles
Convention Center. The meeting showcases
approximately 5,000
abstracts and hundreds of lectures on the latest
advances in GI
research, medicine and technology. For more
information on DDW,
visit www.ddw.org .
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the
world's 20 leading
pharmaceutical companies. Headquartered in
Ingelheim, Germany, it
operates globally with 143 affiliates in 47
countries and almost
37,500 employees. Since it was founded in 1885,
the family-owned
company has been committed to researching,
developing, manufacturing
and marketing novel products of high therapeutic
value for human and
veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales
of 9.5 billion euro
while spending almost one fifth of net sales in
its largest business
segment Prescription Medicines on research and
development.
The Consumer Health Care business is one of the
core businesses of
the Boehringer Ingelheim Corporation and strives
to serve customers
worldwide with top-quality pharmaceuticals for
self-medication and is
widely known for its products such as: Pharmaton(R),
Dulcolax(R),
Bisolvon(R), Mucosolvan(R), Buscopan(R),
Antistax(R) and
Mucoangin(R).
Boehringer Ingelheim Consumer Healthcare is
ranked the
8th largest supplier of self-medication products.
For more
information, visit www.boehringer-ingelheim.com
.
SOURCE Boehringer Ingelheim GmbH
05/23/2006
CONTACT: For any further information, and
details of references
please contact: Ute E. Schmidt, Boehringer
Ingelheim GmbH,
+49-0-6132-77-97296, or Fax, +49-0-6132-77-6601
Web site:
http://www.boehringer-ingelheim.com/corporate/home/home.asp
http://www.ddw.org
BNED: NG
FONTE: PR NEWSWIRE LATIN AMERICA
CORAL GABLES - MIAMI-US
CONTATOS: USA-MARY D'LEON
BRASIL-NÉLIA GARCIA
TELS: USA:1-305-507-2550/BRASIL:55-21-2132-8461
FAXES: USA:1-305-461-8670/BRASIL:55-21-2132-8469
E-MAILS: nelia_garcia@prnewswire.com.br
mary_dleon@prnewswire.com
PALAVRA-CHAVE: RJ
PALAVRA-CHAVE/RAMO DE ATIVIDADE: SAÚDE
PALAVRA-CHAVE/EMPRESA: BOEHRINGER INGELHEIM GMBH
O texto acima, distribuído pela PR Newswire
Brasil, é de inteira responsabilidade de seu
cliente. A utilização deste material não implica
em custo.
|
|
|
|
